- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Abbott completes acquisition of Visiogen
Abbott Laboratories has completed its acquisition of privately held eye-care company Visiogen, adding to its vision-care business an accommodating IOL technology (Synchrony) designed to address presbyopia in patients with cataracts.
Abbott Park, IL
-Abbott Laboratories has completed its acquisition of privately held eye-care company Visiogen, adding to its vision-care business an accommodating IOL technology (Synchrony) designed to address presbyopia in patients with cataracts.
The $400 million cash purchase boosts Abbott’s presence in the vision-care segment, which it entered in February with the acquisition of Advanced Medical Optics, according to a prepared statement from the company.
“Visiogen immediately provides Abbott Medical Optics [AMO] with a talented team of dedicated professionals and an entry point into the accommodating IOL market,” said Jim Mazzo, senior vice president, AMO.
The proprietary accommodating IOL received CE mark designation and has been available commercially in Europe since January. It is under review by the FDA.
